The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?
Open accessAbstract
Pre-existing immunity against human adenovirus (HAd) serotype 5 derived vector in the human population is widespread, thus hampering its clinical use. Various components of the immune system, including neutralizing antibodies (nAbs), Ad specific T cells and type I IFN activated NK cells, contribute to dampening the efficacy of Ad vectors in individuals with pre-existing Ad immunity. In order to circumvent pre-existing immunity to adenovirus, numerous strategies, such as developing alternative Ad serotypes, varying immunization routes and utilizing prime-boost regimens, are under pre-clinical or clinical phases of development. However, these strategies mainly focus on one arm of pre-existing immunity. Selection of alternative serotypes has been largely driven by the absence in the human population of nAbs against them with little attention paid to cross-reactive Ad specific T cells. Conversely, varying the route of immunization appears to mainly rely on avoiding Ad specific tissue-resident T cells. Finally, prime-boost regimens do not actually circumvent pre-existing immunity but instead generate immune responses of sufficient magnitude to confer protection despite pre-existing immunity. Combining the above strategies and thus taking into account all components regulating pre-existing Ad immunity will help further improve the development of Ad vectors for animal and human use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Gebhardt, T., Wakim, L. M., Eidsmo, L., Reading, P. C., Heath, W. R., & Carbone, F. R. (2009) · Nature Immunology · doi:10.1038/ni.1718 · Cited by 1,157
T cell– and B cell–independent adaptive immunity mediated by natural killer cells
O'Leary, J. G., Goodarzi, M., Drayton, D. L., & von Andrian, U. H. (2006) · Nature Immunology · doi:10.1038/ni1332 · Cited by 919
Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891
Cytokine-induced memory-like natural killer cells
Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A., & Yokoyama, W. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813192106 · Cited by 831
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
Mackay, L. K., Stock, A. T., Ma, J. Z., Jones, C. M., Kent, S. J., Mueller, S. N., Heath, W. R., Carbone, F. R., & Gebhardt, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202288109 · Cited by 635
Cited by
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01781 · Cited by 224
Beladiya, J., Kumar, A., Vasava, Y., Parmar, K., Patel, D., Patel, S., Dholakia, S., Sheth, D., Boddu, S. H. S., & Patel, C. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2507 · Cited by 96
Sharma, A., & Knollmann-Ritschel, B. (2019) · Viruses · doi:10.3390/v11020164 · Cited by 88
Metadata
- Authors
- Fausther-Bovendo, H., & Kobinger, G. P.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2014-10-03
- Volume
- 10
- Issue
- 10
- Pages
- 2875-2884
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- OpenAlex
- W1557780170
- Cited by
- 276
- References
- 94
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important? https://app.cochat.ai/papers/10.4161/hv.29594
- The paper
- Fausther-Bovendo, H., & Kobinger, G. P. (2014). Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important? Human Vaccines & Immunotherapeutics. https://doi.org/10.4161/hv.29594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
